anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic inflammatory pain is the highest priority for people with osteoarthritis when seeking medical attention. Despite the availability of NSAIDs and glucocorticoids, central sensitization and peripheral sensitization make pain increasingly difficult to control. Previous studies have identified the ubiquitination system as an important role in the chronic inflammatory pain. Our study displayed that the E3 ubiquitin ligase tripartite motif-containing 14 (Trim14) was abnormally elevated in the serum of patients with osteoarthritis and pain, and the degree of pain was positively correlated with the degree of Trim14 elevation. Furthermore, CFA-induced inflammatory pain rat model showed that Trim14 was significantly increased in the L3-5 spinal dorsal horn (SDH) and dorsal root ganglion (DRG), and in turn the inhibitor of nuclear factor Kappa-B isoform α (IκBα) was decreased after Trim14 elevation. After intrathecal injection of Trim14 siRNA to inhibit Trim14 expression, IκBα expression was reversed and increased, and the pain behaviors and anxiety behaviors of rats were significantly relieved. Overall, these findings suggested that Trim14 may contribute to chronic inflammatory pain by degrading IκBα, and that Trim14 may become a novel therapeutic target for chronic inflammatory pain.
Children and adolescents who regularly skip breakfast are at a greater risk of obesity than those who regularly eat breakfast. Guardian's food literacy, defined in this study as a collection of a guardian's knowledge, skill, and attitude towards healthy food practices, may directly influence their child's dietary habits. Thus, this study utilized a food literacy scale to assess the relationship between guardians' food literacy and breakfast skipping among school-attending Japanese children and adolescents and the most commonly reported reasons for skipping breakfast. This was a cross-sectional study using survey data collected from a nationally representative sample of households in Japan (n = 1520). Our results show that 13.0% of children self-reported skipping breakfast at least once a week. Children in households where guardians reported higher knowledge and attitude scores had significantly lower odds of skipping breakfast (odds ratios = 0.90 [95% confidence interval: 0.83-0.98] and 0.81 [0.74-0.90], respectively). These findings suggest that a guardian's attitude and knowledge towards healthy food practices influence the frequency at which their child eats breakfast. Moreover, lower parental attitude scores were associated with children skipping due to not having enough time for breakfast in the morning. Improving guardians' food literacy may provide an avenue by which to decrease the rate of breakfast skipping among children and adolescents, thereby decreasing the risk of obesity and other adverse health outcomes.
High-grade serous ovarian cancer (HGSOC) has a high death rate and poor prognosis. The main causes of poor prognosis are asymptomatic early disease, no effective screening method at present, and advanced disease. Changes in cellular metabolism are characteristic of cancer, and plasma metabolome analysis can be used to identify biomarkers. In this study, we used Q Exactive liquid chromatography tandem mass spectrometry (LC-MS/MS, QE) to compare the differentiation between plasma samples (22 HGSOC samples and 22 normal samples). In total, we detected 124 metabolites, and an orthogonal partial least-squares-discriminant analysis (OPLS-DA) model was useful to distinguish HGSOC patients from healthy controls. Choline, 25-hydroxyvitamin D2, and sphingomyelin (d18:0/16:1(9Z) (OH))/SM(d18:0/16:1(9Z) (OH)) showed significantly differential plasma levels in HGSOC patients under the conditions of variable importance in projection (VIP) > 1, p < 0.05 using Student's t-test, and fold change (FC)  ≥ 1.5 or ≤ 0.667. Metabolic pathway analysis can provide valuable information to enhance the understanding of the underlying pathophysiology of HGSOC. In conclusion, the Q Exactive LC/MS/MS method validation-based plasma metabolomics approach may have potential as a convenient screening method for HGSOC and may be a method to monitor tumor recurrence in patients with HGSOC after surgery SIGNIFICANCE: High-grade serous ovarian cancer (HGSOC) has a high death rate and poor prognosis. The main causes of poor prognosis are asymptomatic early disease, no effective screening method at present, and advanced disease. Changes in cellular metabolism are characteristic of cancer, and plasma metabolome analysis can be used to identify biomarkers. In this study, we used Q Exactive liquid chromatography tandem mass spectrometry (LC-MS/MS, QE) to compare the differentiation between plasma samples (20 HGSOC samples and 20 normal samples). In total, we detected 124 metabolites, and an orthogonal partial least-squares-discriminant analysis (OPLS-DA) model was useful to distinguish HGSOC patients from healthy controls. Choline, 25-hydroxyvitamin D2, and sphingomyelin (d18:0/16:1(9Z) (OH))/SM(d18:0/16:1(9Z) (OH)) showed significantly differential plasma levels in HGSOC patients under the conditions of variable importance in projection (VIP) > 1, p < 0.05 using Student's t-test, and fold change (FC) ≥ 1.5 or ≤ 0.667. Metabolic pathway analysis can provide valuable information to enhance the understanding of the underlying pathophysiology of HGSOC. In conclusion, the Q Exactive LC/MS/MS method validation-based plasma metabolomics approach may have potential as a convenient screening method for HGSOC and may be a method to monitor tumor recurrence in patients with HGSOC after surgery.
The present invention relates to a cell capable of producing recombinant human LAMAN (rhLAMAN), said cell comprising the 3066 basepair EcoRI - XbaI fragment of a human cDNA which codes for a human LAMAN protein in which the position corresponding to position 186 of the full length hLAMAN protein is Aspartic acid (Asp, D). In particular, the invention relates to a cell comprising a DNA sequence which codes for the amino acid sequence shown in SEQ ID NO. 12. One embodiment is an expression plasmid pLamanExp1 having the sequence shown in SEQ ID NO. 2. One aspect of the invention relates to a method for the preparation of recombinant human LAMAN, the method comprising a) introducing, into a suitable vector, a nucleic acid fragment comprising a DNA fragment which codes for the amino acid sequence shown in SEQ ID NO. 12, b) transforming a cell with the vector obtained in step a), c) culturing the transformed host cell under conditions facilitating expression of the nucleic acid sequence, d) recovering the expression product from the culture. The method may further comprise a fermentation step and/or a purification step. The invention further relates to a rhLAMAN produced by the method of the invention and to the use of the rhLAMAN produced according to the invention for the preparation of a medicament for the treatment of alfa mannosidosis.
Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral gabapentin once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral gabapentin either two or three times daily on days 2-5 of chemotherapy.
In a multicenter double-blind randomized study reported by Julian et al, the effect of sotalol 320 mg once daily was compared with that of placebo in 1456 patients (randomized 3:2, sotalol to placebo) surviving an acute myocardial infarction (MI). Treatment was started 5-14 days after infarction. Patients were followed for 12 months. The mortality rate was 7.3% in the sotalol group and 8.9% in the placebo group, not a statistically significant difference. Although the results do not show evidence of a benefit of sotalol in this population, they do not show an added risk in post MI patients receiving sotalol. There was, however, a suggestion of an early (i.e., first 10 days) excess mortality (3% on sotalol vs. 2% on placebo).

In a second small trial (n=17 randomized to sotalol) where sotalol was administered at high doses (e.g., 320 mg twice daily) to high-risk post-infarction patients (ejection fraction <40% and either >10 VPC/hr or VT on Holter), there were 4 fatalities and 3 serious hemodynamic/electrical adverse events within two weeks of initiating sotalol.
PROBLEM TO BE SOLVED: To obtain a composition for a cosmetic material capable of suppressing yellow discoloration phenomenon thereof for protecting the skin and/or hair from a light, especially from ultraviolet rays. SOLUTION: This composition containing a dibenzoylmethane derivative and a titanium oxide nanopigment contains 0.1-10wt.% dibenzoylmethane derivative of formula I (R1 to R4 are each H, a 1-8C alkyl or a 1-8C alkoxy) and 0.1-30wt.% titanium oxide pigment in a cosmetic medium. This pigment is coated and/or treated with a silicone. Also, preceding to the silicone treatment, the pigment is allowed to be coated with a coating agent other than the silicone such as an alumina, silica, etc. Further, a benzylidene camphor-type compound of formula II (D, E are each H, a 1-20C alkyl, etc.) is excluded from the compounds of formula I. As the compound of formula II, 4-methoxy-4'-tert- butyldibenzoylmethane is preferable. This cosmetic composition can be used as a light fast composition or a makeup product.
A range of doses of AG519 will be tested based on the assessment of safety and tolerability. A single dose of AG-519 will be administered by mouth (orally).
A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a substantially non-toxic adjuvant molecule having biological activity in mucosal tissues, and administering sa id antigen-adjuvant composition to the vertebrate subject in a manner such that  initial contact occurs in mucosal tissue of the vertebrate subject, whereby an immune response is elicited. Cytokines are preferred adjuvants. Preferred cytokines are interleukin-1.alpha. (IL-1.alpha.) and interleukin-1.beta. (IL - 1.beta.).
INTRODUCTION: Fluid accumulation is associated with adverse outcomes in critically ill patients admitted to the intensive care unit (ICU). Fluid administration in the ICU may be a clinically relevant source of fluid accumulation in ICU patients. However, the extent is unknown, and no standard definition exists. We aim to provide epidemiological data on fluid accumulation, risk factors, use of fluid removal strategies, patient outcomes and describe current fluid administration practices in the ICU.
METHODS: We will conduct an international 14-day inception cohort study including a minimum of 1000 acutely admitted adult ICU patients. Data will be collected from medical records and laboratory reports at baseline and daily from ICU admission to discharge with a maximum of 28 days. Follow-up will be performed on day 90 after inclusion. The primary outcome is the number of patients with fluid accumulation. Secondary outcomes include the number of days with fluid accumulation, use of active fluid removal, days alive without life support at day 28, days alive and out of hospital day 90, and all-cause mortality at day 90. Furthermore, we will assess risk factors for fluid accumulation and its association with 90-day mortality and report on the types of fluid administration.
CONCLUSION: This international inception cohort study will provide contemporary epidemiological data on fluid administration and fluid accumulation in adult ICU patients.
<P>PROBLEM TO BE SOLVED: To provide an antiallergic composition, based on consideration of pharmacological action of Xiangru (an extract of whole grass of Mosla chinensis Maxim. ) which is a crude medicine, particularly Mosla chinensis Maxim. or Elsholtzia ciliata Hylander and having excellent antiallergic action based on chemical mediator isolation-suppressing action which the extract has and degranulation-inhibiting action.  <P>SOLUTION: The antiallergic composition comprises an extract of Xiangru with a solvent as an active ingredient, and the Xiangru to be extracted is Mosla chinensis Maxim. or Elsholtzia ciliata Hylander and the solvent for extraction is water, a lower alcohol or a mixture of the lower alcohol with water, preferably ethanol. The antiallergic composition includes a food, especially a food for specified health use, a medicine, a cosmetic, etc.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Nociplastic pain, a third mechanistic pain descriptor in addition to nociceptive and neuropathic pain, was adopted in 2017 by the International Association for the Study of Pain (IASP). It is defined as "pain that arises from altered nociception" not fully explained by nociceptive or neuropathic pain mechanisms. Peripheral and/or central sensitization, manifesting as allodynia and hyperalgesia, is typically present, although not specific for nociplastic pain. Criteria for possible nociplastic pain manifesting in the musculoskeletal system define a minimum of 4 conditions: (1) pain duration of more than 3 months; (2) regional, multifocal or widespread rather than discrete distribution of pain; (3) pain cannot entirely be explained by nociceptive or neuropathic mechanisms; and (4) clinical signs of pain hypersensitivity present in the region of pain. Educational endeavors and field testing of criteria are needed. Pharmacological treatment guidelines, based on the three pain types, need to be developed. Currently pharmacological treatments of nociplastic pain resemble those of neuropathic; however, opioids should be avoided. A major challenge is to unravel pathophysiological mechanisms driving altered nociception in patients suffering from nociplastic pain. Examples from fibromyalgia would include pathophysiology of the peripheral as well as central nervous system, such as autoreactive antibodies acting at the level of the dorsal root ganglia and aberrant cerebral pain processing, including altered brain network architecture. Understanding pathophysiological mechanisms and their interactions is a prerequisite for the development of diagnostic tests allowing for individualized treatments and development of new strategies for prevention and treatment.
The invention discloses strain duck source H4N6 subtype avian influenza virus strain and an application thereof. Does is the preserving number of described virus stain CGMCC? NO.7606. This Strain is duck source H4N6 subtype avian influenza virus, contain CDS sequence as SEQ? ID? NO.1～SEQ? ID? 8 fragments shown in NO.8, correspond respectively to PB2, PB1, PA, HA, NP, NA, M and NS. The present invention has carried out whole genome sequence mensuration to this Strain, and its information is used for studying detection, distribution, the regularty of epidemic of avian influenza virus and controls the popular of bird flu and spread. Strain of the present invention has been supplemented the extremely valuable hereditary information of China H4N6 subtype avian influenza virus, for molecular evolution and the epidemiological study of H4N6 subtype avian influenza virus provide valuable data, fast diagnosis reagent and the vaccine research that can also infect for the preparation of H4N6 subtype avian influenza virus.
PURPOSE:To provide a stable bath liquid composition giving increased concentration at the surface of the skin and exhibiting excellent warmth-retaining effect, by adding a cationic surfactant and an organic warmth-retaining agent to an aqueous dispersion of a specific nonionic surfactant vesicle. CONSTITUTION:The objective composition is produced by mixing (A) an aqueous dispersion of nonionic surfactant vesicle consisting of (i) 100pts.wt. of an ethoxylate selected from polyoxyethylene (hardened) castor oil (preferably having an added ethylene oxide molar number of 8-15) and (ii) 3-30pts.wt., preferably 5-25pts.wt. of a long-chain fatty acid sorbitan polyester (preferably having an esterification degree of 2.8-3.2) with (B) <=30wt% (based on the whole surfactants) cationic surfactant (e.g. long-chain alkylamine, monoalkylated quaternary ammonium salt, etc.) and (C) an organic warmth-retaining agent such as essential oil, vegetable extract, etc. Positive surface charges are imparted to the vesicle particles to improve the adsorptivity of the vesicle to the surface of the skin.
Simvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor leading to inhibition of post-translational modification of small G proteins. Mevalonate-derived prenyl groups, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), facilitate essential intracellular functions of various proteins such as Ras and Rho. Owing to its effect on post-transcriptional modifications of Ras and Rho, the anti-tumor effect of statins has been suggested in various cancer cell lines. However, more recent studies utilizing cancer gene signatures have systematically screened an array of drugs for potential anti-tumor effect and have discovered statins as potential novel targeted agent against cancer. Given the cardiovascular therapeutic dose is 1 mg/kg/day which translates into serum level of 0.1 uM in patients, the investigators have previously tested and reported that low dose lovastatin ranging from nanomolar to 0.3- 1 uM statin induced cell senescence or cytostatic effect of prostate cancer cells in vitro. In addition, the investigators previously reported on well tolerability and promising anti-tumor effect of combination of simvastatin 40 mg daily and standard FOLFIRI (irinotecan, infusional 5-fluorouracil, leucovorin) in metastatic colorectal cancer.
Leflunomide is contraindicated in patients with known hypersensitivity to leflunomide or any of the other components of leflunomide.

Leflunomide can cause fetal harm when administered to a pregnant woman. Leflunomide, when administered orally to rats during organogenesis at a dose of 15 mg/kg, was teratogenic (most notably anophthalmia or microophthalmia and internal hydrocephalus). The systemic exposure of rats at this dose was approximately 1/10 the human exposure level based on AUC. Under these exposure conditions, leflunomide also caused a decrease in the maternal body weight and an increase in embryolethality with a decrease in fetal body weight for surviving fetuses. In rabbits, oral treatment with 10 mg/kg of leflunomide during organogenesis resulted in fused, dysplastic sternebrae. The exposure level at this dose was essentially equivalent to the maximum human exposure level based on AUC. At a 1 mg/kg dose, leflunomide was not teratogenic in rats and rabbits.

When female rats were treated with 1.25 mg/kg of leflunomide beginning 14 days before mating and continuing until the end of lactation, the offspring exhibited marked (greater than 90%) decreases in postnatal survival. The systemic exposure level at 1.25 mg/kg was approximately 1/100 the human exposure level based on AUC.

Leflunomide is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Individuals with a diagnosis of impaired glucose tolerance, impaired fasting glucose or type 2 diabetes mellitus. No intervention.
Phase I Dose-finding study: The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.

Once the MTD has been determined for each cohort, we will recruit an additional 12 patients for each cohort and study the PK profile of both drugs. The 12 patients in each cohort will be sequentially alternated to group 1 or group 2 treatment schedules. Group 1 (N=6 patients in each cohort) will receive vinorelbine three times per week starting on Monday (Day 1) followed by Wednesday (Day 3) and Friday (Day 5). In the subsequent weeks vinorelbine will be given on the same working days (i.e. Monday, Wednesday and Friday). The first PK profile of vinorelbine (without concomitant sorafenib) will be determined on Day 15 under steady state conditions.
OBJECTIVE: Recent studies have reported that gout is associated with a risk of cardiovascular disease (CVD) later in life. However, the predictive value of genetic predisposition to gout combined with lifestyle habits for CVD risk remains unclear. This study aimed to examine the association between genetic predisposition to gout and lifestyle habits and the risk of developing CVD in two diverse prospective cohorts from different ancestries.
METHODS: A total of 224 689 participants of European descent from the UK Biobank and 50 364 participants of East Asian descent from the Korean Genome and Epidemiology Study were included. The genetic risk for gout was assessed using a polygenic risk score (PRS) derived from a meta-genome-wide association study (n=444 533). The incident CVD risk was evaluated according to genetic risk, lifestyle and metabolic syndrome (MetS).
RESULTS: Individuals at high genetic risk for gout had a higher risk of incident CVD than those with low genetic risk across ancestry. Notably, a reduction in CVD risk by up to 62% (HR 0.38; 95% CI 0.31 to 0.46; p <0.001) was observed in individuals at both low and high genetic risk for gout when they maintained ideal MetS and favourable lifestyle habits.
CONCLUSIONS: Our findings indicate that a higher genetic risk of gout is significantly associated with an increased risk of CVD. Moreover, adherence to a favourable lifestyle can significantly reduce CVD risk, particularly in individuals with high genetic risk. These results underscore the potential of PRS-based risk assessment to improve clinical outcomes through tailored preventative strategies.
The invention comprises urea formaldehyde condensation products containing free hydroxymethylene groups in their molecules, possessing a solubility in water at 20 DEG C. of 0,05 to 0,5% weight/volume and a melting point within the range 120 DEG  to 150 DEG C. The principal recurring unit of the polymer has the empirical formula (C3H6O2N2)n The products can be prepared by condensing urea with formaldehyde in acid aqueous solution to form a precondensate, condensing the precondensate in alkaline medium with a further quantity of urea to form a bactericidal condensation product and removing it from its aqueous solution.  Preferably the first step is carried out at pH 3 to 4, especially 3,7, with about 2 to 3, preferably 2,7 mols. of formaldehyde per mol. of urea.  The reaction mixture, after neutralization, is concentrated and further urea is added to give a final ratio of urea to formaldehyde of between 1,25 and 2,0, preferably about 1,6.  After adjustment to an alkaline pH, suitably 8,0, the second stage of the reaction is effected, suitably by spraying the reaction mixture into a high temperature drying tower, advantageously one with an air space at 180 DEG  to 200 DEG C.ALSO:Bacteriostatic products for phoramacentical purposes comprise as active ingredient ureaformaldehyde condensation products containing free hydroxymethylene groups in their molecules, possessing a solubility in water at 20 DEG  C. of 0.05 to 0.5% weight/volume and a melting point within the range 120 DEG  to 150 DEG  C. The composition may take the form of a dusting powder (with talc or a similar base) or an ointment, suspension, tablets, capsules, syrups or elixirs.  The preparation of the condensation products is described (see Group IV (a)).